News & Media / Newsroom
Alfasigma S.p.A. (“Alfasigma”) and Intercept Pharmaceuticals, Inc. ( “Intercept”) announced today the completion of the acquisition of Intercept by Alfasigma through its wholly owned subsidiary Interstellar Acquisition Inc.
Bologna, Italy – November 8, 2023 — Alfasigma S.p.A. (“Alfasigma”) announced today that it has, through its wholly owned subsidiary Interstellar Acquisition Inc. (“Interstellar”), successfully completed its tender offer to purchase all outstanding shares of common stock of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) (“Intercept”), at a price of USD 19.00 per share, net to the seller thereof in cash, without interest, less any applicable withholding of taxes.
Alfasigma S.p.A. ("Alfasigma"), a global pharmaceutical company headquartered in Italy, announced today that it has signed a letter of intent to acquire the Jyseleca® business from Galapagos (Euronext & NASDAQ: GLPG), a global biotechnology company headquartered in Belgium, developing transformational medicines in immunology and oncology.
Bologna, Italy– October 11, 2023 — Alfasigma S.p.A. (“Alfasigma”) today
Bologna, Italia e Morristown, New Jersey, Stati Uniti d’America –
CARE&GO is Alfasigma's innovative summer social campaign, which will accompany travelers during the summer period, giving advice easy to put into practice everyday.
Corporate Communication & Institutional Relations
Staff
[email protected] +39.051.6489.511Press Office
[email protected]You’re entering Alfasigma global website
I agree